ProciseDx

Happy Thanksgiving! 🍂🦃 May your day be filled with gratitude, delicious food, and the warmth of loved ones. Here's to making beautiful memories and counting our blessings. All of us at ProciseDx would like to take this opportunity to send a special thank you to all of you. We wish you a very Happy Thanksgiving, and hope it is filled with love and gratitude.

We're heading to Orlando for the Advances in Inflammatory Bowel Diseases (AIBD) conference from December 9-11.   ProciseDx is transforming therapeutic drug monitoring (TDM) with our game-changing, only FDA-cleared, CLIA Moderately Complex test, delivering Infliximab and Adalimumab results in just 5 minutes—right in your clinic or care lab! This eliminates the lengthy turnaround times associated with traditional methods, providing actionable results when and where it matters most!   Swing by Booth #519 for a live demo!

We're excited to announce that we'll be at the Future Labs Live Show in Philadelphia on October 30th-31st! Come visit our booth to check out the ProciseDx device and discover how EUROIMMUN can support your lab's success with cutting-edge solutions! 📍 Location: Philly 🗓️ Date: October 30th-31st 🔎 Let's connect and see how we can help elevate your lab!

What is TDM? Therapeutic drug monitoring (TDM) includes the quantitation of drug levels in venous serum samples. Through our partnership with @ProciseDx, EUROIMMUN now offers an FDA-cleared analyzer and infliximab and adalimumab TDM assay kits. Request a demo today: https://bit.ly/47nhYUx #TDM #biologics #infliximab #adalimumab #ProciseDx

Are you going to Chicago for ADLM next week? Get a free expo pass on us! Be sure to visit ProciseDx at booth #1655 and find out how you can take control of TDM in less than 5 minutes!   GET YOUR FREE EXPO PASS >  Use Code: 15172E   www.ProciseDx.com #ADLM #TDM #IBD

PROCISEDX ANNOUNCES DISTRIBUTION AGREEMENT WITH EUROIMMUN US INC. FOR THE DISTRIBUTION OF THE PROCISEDX PLATFORM IN THE UNITED STATES AND CANADA San Diego, April 29  2024 ProciseDx, a 100% subsidiary of Biosynex and an innovator in the development of reliable, rapid and easy-to-use delocalized biology systems, announces a strategic agreement with EUROIMMUN US INC. for the exclusive distribution of the ProciseDx platform in the US and Canadian markets. The ProciseDx platform was the first to receive de novo FDA approval in September 2023 for assays for infliximab (Remicade® and biosimilars Renflexis® and Inflectra®) and adalimumab (Humira® and biosimilar Amgevita®) used in Therapeutic Drug Monitoring (TDM), These tests are used to quantify the serum concentration of infliximab (IFX) and adalimumab (ADL) in patients with inflammatory bowel disease (IBD) treated with these drugs. These tests are intended for use in hospitals and other clinical laboratories of moderate complexity. In the United States, 4.3 million people suffer from IBD (Crohn's disease and ulcerative colitis), and up to 15% of them are treated with IFX and ADL. Biological drugs such as Remicade® and Humira® are biotechnology-derived products for the treatment of chronic diseases. They represent the main cost factor in the treatment of IBD, according to a cost study carried out by the Crohn's and Colitis Foundation. The cost of treatment in the United States for IBD patients taking biologics is between $20,000 and $60,000 a year. The measurement of these drugs can help doctors understand why certain patients respond or don't respond to treatment, enabling more personalized treatment. PociseDx will leverage the strong presence and experience of EUROIMMUN US INC. in the distribution of in vitro diagnostic systems in the United States and Canada. Thanks to its sales force (11 US sales representatives and 3 sales representatives in Canada), EUROIMMUN US INC. will target the main market segments (hospital laboratories, reference laboratories, physician office laboratories). In addition, ProciseDx will retain direct access to some thirty prospects with whom it has initiated referral discussions.   "We are delighted with this partnership with EUROIMMUN US INC., which will enable us to extend our commercial coverage in North America and enable IBD patients to benefit from better management of their pathology thanks to immediate results. This agreement with EUROIMMUN US INC. reinforces our strategic partnership in the field of TDM with EUROIMMUN GmbH (parent company of EUROIMMUN US INC.) and its subsidiary IDS (Immuno Diagnostics Systems) initiated several years ago to market the iTracker range in numerous countries. It illustrates the strong synergies resulting from the acquisition of ProciseDx and the merger with Theradiag" comments Larry Abensur, Chairman and CEO of BIOSYNEX.

We are looking for a Sales Development Representative who will be responsible for securing leads by identifying and qualifying sales opportunities and passing them to Regional Sales Managers with the goal of converting the opportunities to new business closes. Familiarity of the in-vitro diagnostics and medical device industry is strongly desired. Click the link to apply!